1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Malignant Melanoma Pricing and Reimbursement

Malignant Melanoma Pricing and Reimbursement

  • September 2015
  • -
  • Datamonitor Healthcare
  • -
  • 55 pages

Prices of melanoma therapies and oncology drugs on the whole have become subject to closer scrutiny due to their high costs. Currently, the treatment of melanoma has a limited budgetary impact and Datamonitor Healthcare does not anticipate any immediate impact on the pricing of melanoma therapies. However, in the future, manufacturers may have to consider novel pricing arrangements for high-cost combination treatments.

This report addresses the following questions:
- What are the main utilization management tools used by US payers for melanoma drugs and how will their use evolve in the future?
- How concerned are the US payers regarding the growing budget impact of melanoma therapies?
- Which melanoma drugs were the most successful in European health technology assessments and why?
- In which countries are melanoma drugs reimbursed under risk-sharing agreements?
- What levers are most commonly used by EU payers to limit the budget impact of melanoma therapies?

Table Of Contents

Malignant Melanoma Pricing and Reimbursement
EXECUTIVE SUMMARY
MARKET CONTEXT
1. Market entry of new drugs will dramatically increase the budget impact of melanoma
Treatments, 2. Marketed malignant melanoma products in the US, Japan, and five major EU markets, 3. Pipeline malignant melanoma treatments in late-stage development, 4. Price assumptions, 5. Bibliography

US
6. Pricing, 7. Reimbursement, 8. Bibliography

JAPAN
9. Successful pricing outcomes hinge on receipt of a pricing premium, 10. Nivolumab was awarded a 60% innovation margin, 11. Bibliography

FIVE MAJOR EU MARKETS
12. Pricing, 13. Reimbursement and health technology assessment, 14. Bibliography

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Hepatitis C: Kol Insight

September 2016 $ 8085

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.